Researchers from Abl Bio Inc. have published preclinical data for ABL-112, an Fc-competent bispecific antibody (BsAb) targeting TIGIT and 4-1BB (TIGIT x 4-1BB), being developed for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback